Compare PIII & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | BRNS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 30.4M |
| IPO Year | 2021 | 2021 |
| Metric | PIII | BRNS |
|---|---|---|
| Price | $9.49 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | 34.0K | ★ 55.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $0.51 |
| 52 Week High | $16.89 | $1.83 |
| Indicator | PIII | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 59.44 |
| Support Level | $9.00 | $0.65 |
| Resistance Level | $11.55 | $0.74 |
| Average True Range (ATR) | 0.58 | 0.05 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 34.26 | 67.06 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.